<SEC-DOCUMENT>0001104659-21-077763.txt : 20210607
<SEC-HEADER>0001104659-21-077763.hdr.sgml : 20210607
<ACCEPTANCE-DATETIME>20210607170138
ACCESSION NUMBER:		0001104659-21-077763
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20210604
FILED AS OF DATE:		20210607
DATE AS OF CHANGE:		20210607

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Mann Brenda
		CENTRAL INDEX KEY:			0001668858

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36672
		FILM NUMBER:		211000218

	MAIL ADDRESS:	
		STREET 1:		C/O EYEGATE PHARMACEUTICALS, INC.
		STREET 2:		271 WAVERLY OAKS ROAD, SUITE 108
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02452

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EYEGATE PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001372514
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		271 WAVERLEY OAKS ROAD
		STREET 2:		SUITE 108
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02452
		BUSINESS PHONE:		781-788-9043

	MAIL ADDRESS:	
		STREET 1:		271 WAVERLEY OAKS ROAD
		STREET 2:		SUITE 108
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02452
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>tm2119042d1_4seq1.xml
<DESCRIPTION>OWNERSHIP DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2021-06-04</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001372514</issuerCik>
        <issuerName>EYEGATE PHARMACEUTICALS INC</issuerName>
        <issuerTradingSymbol>EYEG</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001668858</rptOwnerCik>
            <rptOwnerName>Mann Brenda</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O EYEGATE PHARMACEUTICALS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>271 WAVERLEY OAKS ROAD, SUITE 108</rptOwnerStreet2>
            <rptOwnerCity>WALTHAM</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02452</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>VP of Research &amp; Development</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2021-06-04</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>F</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>155</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>4.19</value>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>15538</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">Sale of shares to cover taxes due on restricted stock that vested on 06/01/2021.</footnote>
        <footnote id="F2">The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.19 to $4.39, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Sarah Romano, Attorney-in-Fact*</signatureName>
        <signatureDate>2021-06-07</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
